John-Akinola Yetunde Olufisayo, Ayede Adejumoke Idowu, Adeyemi Ayomide, Nantume Assumpta, Olaleye Adesewa Oluwatomisin, Akinrinoye Olugbenga, Tongo Olukemi Oluwatoyin, Alao Michael Abe, Oluleye Adenike, Sobande Oluseye, Olayemi Olatayo Sunday, Oketch Bertha Akinyi, Oluwafemi Rosena Olubanke, Eniowo Patricia Ireti, Ojo Samuel, Olubosede Omolayo Adebukola, Bello Emmanuel Olaseinde, Sani Ismaila, Cauvel Teresa, Shah Sona
College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria.
Neopenda, PBC, Chicago, IL, United States.
Front Digit Health. 2025 Jul 28;7:1597651. doi: 10.3389/fdgth.2025.1597651. eCollection 2025.
The first 28 days of a newborn's life are a critical time for their survival and subsequent growth and development. Wearable devices have emerged as a potential solution for clinical monitoring, offering affordability, accessibility, and improved patient care. This study explored the acceptability, satisfaction, and perceived benefits of the neoGuard wearable vital signs monitoring device among parents/guardians of sick newborns in Nigeria.
This was a qualitative study conducted between April and December 2022 at three tertiary level health facilities in Nigeria. In-depth interviews were conducted with 17 parents/guardians whose newborns were monitored using the neoGuard technology. Participants were selected based on specific criteria, including observation of at least 2 h of use of the neoGuard technology on their newborn, and interviews were conducted in the participants' preferred language. Interviews were moderated with a semi-structured interview guide and audio recorded. Data were transcribed, coded and analyzed thematically using NVivo software.
The majority of participants expressed positive reactions to the neoGuard device, although some initial concerns were reported. Participants appreciated the device's functionality, ease of use, and potential to detect health issues in newborns. The device did not interfere with routine care activities such as cleaning, breastfeeding, or kangaroo care. Participants expressed high levels of confidence in the device's safety and expressed satisfaction with its performance. They suggested improvements such as designing the device to be worn on the wrist instead of the forehead.
Overall, the neoGuard wearable vital signs monitor was well accepted by parents/guardians of sick newborns in Nigeria. The device's functionality, ease of use and potential to improve newborn health were positively perceived. Some suggestions for design improvements were provided. These findings highlight the importance of considering the perspectives of parents/guardians, alongside clinicians and other stakeholders, when implementing new technologies in clinical care. Further research should examine the device's clinical impact and cost-effectiveness while considering the experiences and perceptions of both healthcare providers and patients' guardians to inform adoption into clinical practice.
新生儿生命的头28天对其生存以及随后的生长发育而言是关键时期。可穿戴设备已成为临床监测的一种潜在解决方案,具有价格可承受、易于使用且能改善患者护理的特点。本研究探讨了尼日利亚患病新生儿的父母/监护人对neoGuard可穿戴生命体征监测设备的接受度、满意度及感知到的益处。
这是一项于2022年4月至12月在尼日利亚三家三级医疗机构开展的定性研究。对17位其新生儿使用neoGuard技术进行监测的父母/监护人进行了深入访谈。参与者根据特定标准选取,包括观察到neoGuard技术在其新生儿身上至少使用2小时,访谈以参与者偏好的语言进行。访谈采用半结构化访谈指南进行主持并录音。数据进行转录、编码,并使用NVivo软件进行主题分析。
尽管报告了一些最初的担忧,但大多数参与者对neoGuard设备表达了积极反应。参与者赞赏该设备的功能、易用性以及检测新生儿健康问题的潜力。该设备不会干扰诸如清洁、母乳喂养或袋鼠式护理等常规护理活动。参与者对设备的安全性表达了高度信心,并对其性能表示满意。他们建议进行改进,例如将设备设计为可戴在手腕而非前额上。
总体而言,neoGuard可穿戴生命体征监测仪在尼日利亚患病新生儿的父母/监护人中得到了很好的接受。该设备的功能、易用性以及改善新生儿健康的潜力得到了积极认可。还提供了一些设计改进建议。这些发现凸显了在临床护理中实施新技术时,考虑父母/监护人以及临床医生和其他利益相关者观点的重要性。进一步的研究应在考虑医疗保健提供者和患者监护人的经验与看法的同时,考察该设备的临床影响和成本效益,以为其纳入临床实践提供依据。